Replies to post #277373 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Perhaps none.

I expect some PD or PDD related info from Anavex before or immediately after the conference to put things in proper perspective

Actually, Anavex may, intelligently, elect to say absolutely nothing before or after the CTAD conference. Statements that come directly from the company are still questioned, as merely news-shaping utterances. Those will be perceived by many as merely self-serving, cherry-picked, good-news things.

Instead, silence by the company allows all of the discussion to center on the CTAD conference data. The medical experts there will be doing the talking, being interviewed by news reporters.

Here's the news media scenario. "Dr. Dorglemeyer, you are an expert on Alzheimer's disease. What was your take on the Anavex drug blarcamesine? It looked to be pretty successful in treating the dementia of Parkinson's disease. Could it do the same for the dementia of Alzheimer's?"

A year ago, Dr. Dorglemeyer would have responded, "Well, the clinical data on blarcamesine are weak and incomplete. Its putative mechanism of action is still quite questionable. A lot more work needs to be done to prove the concept."

Not this year. The "more work" has been done; revealed in the new Parkinson's disease dementia data; which the good doctor has just been confronted with at the CTAD conference. After the CTAD conference, the Anavex deniers will have nothing truthful to say, other than, "Well, this stuff does work. Now, let's see the Anavex data from the big Alzheimer's study coming to an end."

The Anavex ducks are aligned; dots connected. Rett, Parkinson's disease dementia, and finally, Alzheimer's disease, all successfully treated with blarcamesine.